denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
This session will focus on evolving issues and controversies in anticoagulation including laboratory measurement and reversal of the direct oral anticoagulants (DOACs), their use in high-risk populations, and the changing landscape of anticoagulation in children.
Dr. Adam Cuker will provide an overview of the effect of the DOACs on coagulation assays and a practical guide on how to interpret and use assay results within the clinical context. He will also discuss strategies for managing the patient with DOAC-associated bleeding, including reversal agents.
Dr. Guy Young will describe the changing landscape of anticoagulation in the pediatric population including data from recently completed prospective clinical trials. He will review anticoagulant options in children and adolescents and briefly discuss the future role of DOACs in children.
Dr. Harry Büller will discuss evidence for the use of DOACs in high-risk states including mechanical heart valves, malignancy, antiphospholipid syndrome, and heparin-induced thrombocytopenia. He will briefly share his recommendations for anticoagulation in these conditions.